Search results
Results from the WOW.Com Content Network
Valsartan/hydrochlorothiazide, sold under the brand name Diovan HCT among others, is a medication used to treat high blood pressure when valsartan is not sufficient. [6] It is a combination of valsartan, an angiotensin receptor blocker with hydrochlorothiazide , a diuretic . [ 7 ]
Valsartan, sold under the brand name Diovan among others, is a medication used to treat high blood pressure, heart failure, and diabetic kidney disease. [8] It belongs to a class of medications referred to as angiotensin II receptor blockers (ARBs). It is a reasonable initial treatment for high blood pressure. [8] It is taken by mouth. [8]
Amlodipine/valsartan, sold under the brand name Exforge among others, is a blood pressure lowering combination drug.It contains amlodipine, as the besilate, a dihydropyridine-type calcium channel blocker, and valsartan, an angiotensin II receptor antagonist. [6]
Brand names and generic names are differentiated by capitalizing brand names. See also the list of the top 100 bestselling branded drugs, ranked by sales. Abbreviations are used in the list as follows: INN = International nonproprietary name; BAN = British Approved Name; USAN = United States Adopted Name; Two-letter codes for countries
Language links are at the top of the page across from the title.
Candesartan is an angiotensin receptor blocker used mainly for the treatment of high blood pressure and congestive heart failure.Candesartan has a very low maintenance dose.
There’s an easy way to find out: conduct a reverse phone lookup — for free. But is there a truly free reverse phone lookup? Yes — there are plenty of sites that offer free reverse phone lookups.
In one main study in adult patients with moderate to severe active Crohn's disease in whom conventional therapy or TNF-alpha antagonists were ineffective or could not be tolerated, vedolizumab was shown to be more effective than placebo: 15% (32 out of 220) of patients receiving vedolizumab showed improved symptoms after 6 weeks of treatment, compared with 7% (10 out of 148) of patients on ...